A Proof of Concept Study of Inhaled Nitric Oxide for Adults With Pulmonary Non-Tuberculous Mycoba… (NCT03748992) | Clinical Trial Compass
CompletedPhase 2
A Proof of Concept Study of Inhaled Nitric Oxide for Adults With Pulmonary Non-Tuberculous Mycobacterial Infection
United States10 participantsStarted 2019-01-28
Plain-language summary
The purpose of this study is to evaluate the efficacy and safety of open-label exposure of gNO in patients with NTM lung disease. Subjects will receive the study drug by inhaling through a nasal mask. Subjects will be treated for 3 weeks (5 days per week) and followed monthly for 3 months.
Who can participate
Age range18 Years – 80 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
Subjects are \>18 years of age and able to provide informed consent.
Subjects have NTM lung disease as defined by each of the following:
Sputum cultures positive for NTM (MAC or M abscessus) Radiologic studies that demonstrate features consistent with disease such as nodular bronchiectasis and/or cavities Symptoms consistent with disease including respiratory (e.g. cough, sputum production, hemoptysis, chest pain) and constitutional (e.g. fevers, night sweats, fatigue, myalgias, arthralgias, weight loss) Subjects are able to produce sputum for culture (either spontaneous or induced).
Subjects have a history of persistently positive sputum cultures for NTM defined as \>4 number of cultures over 24 months with \>75% positive AND a positive culture in the last 3 months.
Clinically stable with no significant changes in health status within 14 days prior to Screening or Day 1 Subjects are willing and able to perform requirements of the study.
Exclusion Criteria:
Smoking history in the prior 6 months Significant hemoptysis within 30 days prior to screening (\>5 ml of blood in one coughing episode or \>30 ml of blood in a 24 hour period) Forced expiratory volume at one second (FEV1) \<40% of predicted On supplemental oxygen or SaO2 \<90% at screening or Day 1, or within 30 days prior to enrollment.
Known cardiac (left heart) insufficiency (defined as LVEF \<35%) prior to screening Known pulmonary hypertension Known or suspected hemoglobinopathy Initiation…